Back

Effect of finerenone in patients with chronic kidney disease and type 2 diabetes by baseline anaemia status: a FIDELITY analysis

28 August 2023 (09:06 - 09:24)
Organised by: Logo
Congress Presentation Part of: Novel targets and treatments for heart diseases and diabetes Aldosterone Antagonists ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

4 More presentations in this session

Presentation thumbnail
State-of-the-art lecture on novel targets and treatments for heart diseases and diabetes
Professor J. Pernow (Stockholm, SE)
Slides
Presentation thumbnail
Biochemical profiles and risk of cardiovascular events in patients withType 2 Diabetes: implications for choice of novel antihyperglycemic therapy
Doctor M. Elmegaard (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
GLP1 receptor agonists exhibit antioxidant and anti-inflammatory properties in human heart tissue via the canonical GLP1 receptor expression through a AMPK-mediated pathway
Doctor E. Cordeanu (Strasbourg, FR)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysis
Doctor R. Mentz (Durham, US)
Abstract Slides Video

Access the full session

Session thumbnail
Novel targets and treatments for heart diseases and diabetes
Video

The Event

Event poster

ESC Congress 2023

28 August 2023 09:06 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysis
thumbnail
Congress Presentation
Effect of finerenone on the incidence of hypokalemia in patients with type 2 diabetes and chronic kidney disease: a FIDELITY analysis
thumbnail
Congress Session
Novel targets and treatments for heart diseases and diabetes

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources